Comparative efficacy and safety of 5-day cefaclor and 10-day amoxycillin treatment of group A streptococcal pharyngitis in children

Pediatric Department I, University of Milan, Via Commenda 9, 20122 Milan, Italy.
International Journal of Antimicrobial Agents (Impact Factor: 4.26). 08/2002; 20(1):28-33. DOI: 10.1016/S0924-8579(02)00118-8
Source: PubMed

ABSTRACT A total of 384 children with group A beta-haemolytic streptococcal (GABHS) pharyngitis were randomized to receive either 40 mg/kg/day of cefaclor in two doses for 5 days (192 patients), or 40 mg/kg/day of amoxycillin in three doses for 10 days (192 patients). The signs and symptoms of pharyngitis were recorded and throat cultures were obtained at presentation and on days 6-7, 11-15, 16-20 and 28-35. Patient compliance was significantly higher in the children treated with cefaclor (100 vs. 95.1%; P = 0.003). At the end of follow-up, the percentage of clinical success was 91.4% for cefaclor and 91.9% for amoxycillin (P = 0.974); bacteriological success was obtained in 85.7 and 89.6% children (P = 0.348), respectively. Both treatments were well-tolerated with adverse event rates of 8.3% in the cefaclor group and 9.4% in the amoxcillin group (P = 0.857). Our study shows that five days' treatment with cefaclor is as effective and safe as the conventional 10-day course of amoxycillin in the treatment of GABHS pharyngitis, but compliance seems to be significantly greater.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Group A β-hemolytic streptococcus (GABHS) is the most common bacterial cause of acute pharyngitis in children. Because clinical findings can be nonspecific, even experienced physicians cannot reliably diagnose GABHS pharyngitis solely on the basis of clinical presentation. Suspected cases should be confirmed by a throat culture or a rapid antigen detection test before antibiotic therapy is initiated. Microbiologic testing is generally not necessary in patients with pharyngitis whose clinical and epidemiologic findings are not suggestive of GABHS. Clinical score systems have been developed to help physicians decide which patients should undergo diagnostic testing and to reduce the unnecessary use of antibiotics. Antibiotic therapy should be initiated as soon as the diagnosis is confirmed. Penicillin V remains the drug of choice. Alternative therapy, eg, with cephalosporin or macrolide, is often sought because of penicillin allergy, noncompliance, and treatment failure.
    Advances in Therapy 09/2004; 21(5):277-287. DOI:10.1007/BF02850032 · 2.44 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The solubility of Cefaclor in water, methanol, ethanol and acetone was studied under atmospheric pressure in the 278.15–313.15 K temperature range using a dynamic laser method. The modified Apelblat model and a polynomial equation were used to model the experimental data, and both models provided good fits (R2 > 0.99). The changes in the standard enthalpy, entropy and Gibbs free energy upon dissolution of Cefaclor were calculated to obtain thermodynamics data related to Cefaclor crystallisation. The results show that the dissolution process was endothermic and nonspontaneous, and that the main contributing force was the enthalpy in methanol, ethanol and acetone solvents.
    Fluid Phase Equilibria 01/2015; 388:123-127. DOI:10.1016/j.fluid.2015.01.001 · 2.24 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Treatment guidelines from the Infectious Diseases Society of America, the American Heart Association, and the American Academy of Pediatrics recommend only oral penicillin V or intramuscular benzathine penicillin G as the treatments of choice for group A β-hemolytic streptococcal pharyngitis. Practitioners prescribe amoxicillin most frequently for children. Ten-day treatment courses with first-generation oral cephalosporins or erythromycin are recommended as suitable alternatives in patients who are allergic to penicillin. Yet oral cephalosporins are used as drugs of choice for many patients with group A β-hemolytic streptococcal pharyngitis. This review examines the evidence in order to help the practitioner choose the optimal antibiotic treatment for their patients.
    Clinical Pediatrics 05/2007; 46(4). DOI:10.1177/0009922807299938 · 1.26 Impact Factor

Full-text (2 Sources)

Available from
May 15, 2014